Contact Us
  • Choose License Type

Global Cervical Cancer Diagnostic Tests Market, By Test Type (Pap Smear Test, Colposcopy Test, ECC Test, and HPV Test), By Age Group (Age 20 – 40 and Age Above 40), and By Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa), is estimated to be valued at US$ 5,910.2 million in 2020 and is expected to exhibit a CAGR of 6.2% over the forecast period (2020-2027), as highlighted in a new report published by Coherent Market Insights.

Smoking increases the chances of cervical cancer by a factor of three. The carcinogens in tobacco triggers and aids the HPV to cause cervical cancer. The rising number of smokers and passive smokers are increasing the chances of cervical cancer in a woman, thereby driving the revenue for cervical cancer diagnostic tests market.

According to the Cancer Research UK, around 21% of cervical cancers are caused due to smoking. Moreover, the International Agency for Research on Cancer (IARC) classifies smoking in Group 1, which states that tobacco is carcinogenic to humans.

Also, according to Truth Initiative, the U.S.-based nonprofit public health organization, (March 2019), among high school students in the U.S., 7.3 percent of females and 8.8 percent of males currently smoke cigarettes.

Global Cervical Cancer Diagnostic Tests Market– Impact of Coronavirus (Covid-19) Pandemic

Governments are taking various initiatives to combat COVID-19. For instance, on September 4, 2020, the Ministry of Health & Family Welfare, Government of India as well as other professional societies such as Indian Society for Colposcopy and Cervical Pathology (ISCCP), Federation of Obstetric and Gynecological Societies of India, Asia Oceania research organization on Genital Infections and Neoplasia, India (AOGIN-India), and Association of Gynecologic Oncologists of India (AGOI) came together for the introduction of the National Programme for Screening of Breast, Oral and Cervical Cancers in India.

Also, on August 19, 2020, according to the World Health Organization (WHO), the World Health Assembly, a part of WHO, adopted the global strategy to accelerate the diagnosis and treatment of cervical cancer as a public health problem. The strategy includes three main points: prevention of cervical cancer through vaccination, screening and treatment of precancerous lesions, and treatment and palliative care for invasive cervical cancer. The WHO is planning to achieve the goal of stopping the occurrence of cervical cancer by implementing the above strategies at a large scale.

Moreover, according to the World Health Organization (WHO) initiative, The United Nations Global Cervical Cancer Programme established a new 5-year Joint Programme to prevent and control cervical cancer with seven UN agencies. The Joint Programme will provide global leadership as well as technical assistance to support governments and their partners to build national cervical cancer control programs with women accessing services equitably.

Browse 26 Market Data Tables and 26 Figures spread through 171 Pages and in-depth TOC on “Cervical Cancer Diagnostic Tests Market”- Global Forecast to 2027, By Test Type (Pap Smear Test, Colposcopy Test, ECC Test, and HPV Test), By Age Group (Age 20 – 40 and Age Above 40), and By Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa),

To know the latest trends and insights prevalent in the global cervical cancer diagnostic tests market, click the link below:

https://www.coherentmarketinsights.com/market-insight/cervical-cancer-diagnostic-tests-market-3994

Key players operating in the market are focusing on novel product launch, in order to expand their product portfolio in the global market, which is expected to drive the market growth during the forecast period. In September 2020, F. Hoffmann-La Roche AG received the U.S. Food and Drug Administration approval for the expanded use of CINtec PLUS Cytology, the first triage test based on biomarker technology for women whose cervical cancer screening results are positive for high-risk types of human papillomavirus. 

Key Takeaways of the Global Cervical Cancer Diagnostic Tests Market:

  • The global cervical cancer diagnostic tests market is expected to exhibit a CAGR of 6.2% over the forecast period, as major organizations are focused on offering guidelines for cervical cancer diagnostics. For instance, in June 2020, American Society for Colposcopy and Cervical Pathology issued new guidelines for managing abnormal results on cervical cancer screening, which emphasize more precise management based on estimates of the patient's risk - enabling more personalized recommendations for diagnosis, treatment, and follow-up.
  • Among test type, Pap smear test segment is estimated to account for largest market share in 2020, owing to increasing number of Pap smear test users. For instance, according to the Centers for Disease Control and Prevention data of 2018, around 70.2% women of age 18 and above underwent Pap smear test for diagnosis of cervical cancer within the past 3 years in the U.S. According to the same source, women aged between 25 and 44 take this test most frequently, as compared to other age groups.
  • Key players operating in the global cervical cancer diagnostic tests Market DYSIS Medical Ltd., Abbott Laboratories, Becton, Dickinson and Company, The Cooper Companies, Inc., Danaher Corporation, F. Hoffmann-La Roche AG, Quest Diagnostics, Arbor Vita Corporation, Hologic, Inc., Zilico Ltd, and Qiagen
Existing Clientele

Joining thousands of companies around the world committed to making the Excellent Business Solutions.

View All Our Clients

Our Trusted Patner